A Review of the Impact of Biologics on Surgical Complications in Crohn's Disease

Chang MI1, Cohen BL, Greenstein AJ. Inflamm Bowel Dis. 2015 Mar 25. [Epub ahead of print]
Author information

1Departments of *Surgery, and †Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.


Anti-tumor necrosis factor therapy has revolutionized the treatment of Crohn's disease. Despite the increased use in the past decade and a half, a majority of patients with Crohn's disease with ultimately require operative management of their disease. No clear consensus has been made in the literature regarding the surgical outcomes in patients who have been exposed to anti-tumor necrosis factor therapy. This review highlights the most recent and relevant literature regarding the safety and effects of anti-tumor necrosis factor use in the perioperative period.

© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.